COVID-19 in patients with preexisting liver disease: Clinical features and outcomes from northern Iran

People living with chronic liver disease (CLD) may experience more severe consequences when infected with coronavirus disease 2019 (COVID-19). However, information from Middle Eastern populations is still limited. The present research examined the presentation and outcomes of COVID-19 among patients with underlying liver disorders in Northern Iran. To achieve this, a retrospective cross-sectional review was carried out in a major referral hospital between March 2020 and March 2023. Adult patients with confirmed COVID-19 and documented preexisting liver disease were included. Demographic, clinical, and outcome data were extracted and analyzed. Among 83 identified patients, common symptoms were myalgia (59%), cough (56.6%), and respiratory distress (49.4%). Hypoxemia (25.3%) was significantly associated with mortality (47.4% vs. 18.8%, P = 0.017). Altered consciousness also predicted poor outcomes (31.6% vs. 9.4%, P = 0.016). COVID-19 patients with preexisting liver disease had increased risk of adverse outcomes, with hypoxemia and altered mental status serving as key mortality predictors. Early recognition and tailored management are essential for this vulnerable group.